SVRA NASDAQ
Savara Inc.
1W: -1.3%
1M: -7.0%
3M: +0.6%
YTD: -6.0%
1Y: +38.4%
3Y: +40.2%
5Y: +233.3%
$5.30
-0.02 (-0.38%)
Weekly Expected Move ±4.5%
$5
$5
$5
$6
$6
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.1B
52W Range3.34-7.005
Volume1,063,657
Avg Volume1,653,103
Beta0.25
Dividend—
Analyst Ratings
Company Info
CEOMatthew Pauls
Employees70
SectorHealthcare
IndustryBiotechnology
IPO Date2017-04-28
Websitesavarapharma.com
The Tannery
Yardley, PA 19067
US
Yardley, PA 19067
US
512 614 1848
About Savara Inc.
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Latest News
BlackRock Inc. Takes $76.97 Million Position in Savara Inc. $SVRA
Algert Global LLC Purchases 464,645 Shares of Savara Inc. $SVRA
Deutsche Bank AG Makes New $5.33 Million Investment in Savara Inc. $SVRA
Here's Why You Should Add Savara Stock to Your Portfolio Now
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Lutz Robert Matthew | A-Award | 35,000 | — | 2026-07-15 |
| Lutz Robert Matthew | A-Award | 70,000 | $5.81 | 2026-07-15 |
| Lowrance David L | M-Exempt | 75,000 | $1.59 | 2026-06-22 |
| Lowrance David L | F-InKind | 21,682 | $5.50 | 2026-06-22 |
| Lowrance David L | M-Exempt | 129,350 | $1.23 | 2026-06-22 |